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Background: Biomaterial scaffolds that deliver growth factors such as recombinant human bone morphogenetic
proteins-2 (rhBMP-2) have improved clinical bone tissue engineering by enhancing bone tissue regeneration. This
approach could be further improved if the controlled delivery of bioactive rhBMP-2 were sustained throughout the
duration of osteogenesis from fibrous scaffolds that provide control over dose and bioactivity of rhBMP-2. In nature,
heparan sulfate attached to core proteoglycans serves as the co-receptor that delivers growth factors to support
tissue morphogenesis.
Methods: To mimic this behavior, we conjugated heparan sulfate decorated recombinant domain I of perlecan/
HSPG2 onto an electrospun poly(ε-caprolactone) (PCL) scaffold, hypothesizing that the heparan sulfate chains will
enhance rhBMP-2 loading onto the scaffold and preserve delivered rhBMP-2 bioactivity.
Results: In this study, we demonstrated that covalently conjugated perlecan domain I increased loading capacity
of rhBMP-2 onto PCL scaffolds when compared to control unconjugated scaffolds. Additionally, rhBMP-2 released
from the modified scaffolds enhanced alkaline phosphatase activity in W20–17 mouse bone marrow stromal cells,
indicating the preservation of rhBMP-2 bioactivity indicative of osteogenesis.
Conclusions: We conclude that this platform provides a sophisticated and efficient approach to deliver bioactive
rhBMP-2 for bone tissue regeneration applications.
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Electrospun fiber meshes have gained increasing interest
as tissue engineering scaffolds because of their nano- to
microscale topography that resembles the native extra-
cellular matrix (ECM) and their highly interconnected
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electrospinning applies high voltage to a polymeric solu-
tion, generating electrostatic forces that drive the de-
position of a non-woven fiber mesh consisting of solid
polymeric fibers. The high specific surface area of these
porous scaffolds renders them additionally useful for
drug delivery applications (Sill and von Recum 2008).
To date, a wide variety of natural and synthetic polymers
such as collagen, fibrinogen, hyaluronic acid, poly(glycolic
acid) and poly(ethylene-co-vinyl alcohol) have been elec-
trospun to generate fibrous scaffolds for various tissueis distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
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et al. 2002; McManus et al. 2007; Pham et al. 2006b). As a
biocompatible, biodegradable and low-cost synthetic poly-
mer, poly(ε-caprolactone) (PCL) has emerged as one of
the more widely investigated biomaterials for tissue engin-
eering applications, including the regeneration of skin,
nerve, and musculoskeletal tissues (Cipitria et al. 2011;
Woodruff and Hutmacher 2010). Notably, electrospun
PCL also has been actively explored as a platform for bone
regeneration (Ekaputra et al. 2009; Liao et al. 2010;
Mountziaris et al. 2013; Mountziaris et al. 2010; 2012; Thi-
bault et al. 2010; Xie et al. 2013). However, because the
material itself lacks inherent osteoinductive capacity, ef-
forts have been undertaken to incorporate osteoinductive
factors into the scaffold. Examples of such methods in-
clude coating the fiber surface with a bone-like ECM (Thi-
bault et al. 2013) and enhancing local delivery of
osteoinductive factors from within a biodegradable poly-
mer (Martins et al. 2010). Among the known osteoinduc-
tive signaling factors, recombinant human bone
morphogenetic proteins (rhBMPs) have been investigated
most extensively as agents to encourage new bone forma-
tion. However, the short biological half-lives of these mor-
phogens delivered as free compounds necessitate the use
of supra-physiological doses to induce osteogenesis in the
absence of a controlled-release delivery system. Such high
levels can have serious adverse clinical repercussions,
such as uncontrolled ectopic bone formation and in-
flammation (Haidar et al. 2009; Schmidmaier et al.
2008). To improve safety and reduce costs, rethinking
the design of rhBMP delivery systems that increase
osteoinductivity, while simultaneously achieving local-
ized and controlled release of the delivered growth fac-
tor(s), is a critical undertaking (Haidar et al. 2009).
Various immobilization mechanisms such as physical
entrapment, adsorption, and complexation can be
employed to sustain the long term delivery of non-
covalently attached rhBMPs (Luginbuehl et al. 2004; Kim
et al. 2014). Unfortunately, these methods often exacer-
bate the problem of potential growth factor inactivation
(Luginbuehl et al. 2004). Heparin, a commercially available
free glycosaminoglycan with structural-functional simi-
larity to heparan sulfates found on proteoglycans, has
gained wide use as a heparan sulfate mimetic to study
glycosaminoglycan-growth factor interactions and to
sequester growth factors in controlled delivery systems
(Zhang 2010; Whitelock and Iozzo 2005). Heparin has
been investigated as an adjunct to scaffolds to confer
improved control of growth factor release kinetics
(Zhang 2010; Jeon et al. 2007; Kim et al. 2011). Despite
this, the actual native entities that bind, store, and acti-
vate this class of growth factors and morphogens are
not heparin, but rather the polymeric heparan sulfate
chains attached to proteoglycan core proteins presenton cell surfaces and in the ECM (Zhang 2010). The bio-
logically relevant interactions between morphogens and
heparan sulfate are optimized by nature for both bind-
ing and release, and depend on the precise micropat-
terned structures of 2- and 6-O-sulfate moieties of
heparan sulfate chains (Ashikari-Hada et al. 2004). To
improve biologically relevant interactions both for
binding and release by tissue heparanase, there is a shift
away from using heparin as a global substitute in favor
of more biologically appropriate forms of heparan sul-
fate (Whitelock and Iozzo 2005). Highly expressed in
the human bone marrow and in other mesenchymal tis-
sues, perlecan/HSPG2 is a large, secreted heparan
sulfate proteoglycan with five distinct domains, each
endowed with the unique ability to affect cellular pro-
cesses such as cell binding, proliferation, differentiation,
and angiogenesis (Knox and Whitelock 2006). Perlecan
domain 1 (PlnD1) in particular, harbors three consen-
sus glycosaminoglycan attachment sites that can con-
tain up to three heparan sulfate chains for binding,
storage, and release of heparin-binding growth factors
and morphogens. Bound growth factors provide an “on
demand” depot and are protected from denaturation or
proteolytic degradation, while their biological activity
can be augmented when released by natural enzymatic
means such as heparanase activity (Decarlo et al. 2012;
Knox and Whitelock 2006; Mongiat et al. 2001; Takada
et al. 2003; McKeehan et al. 1999; Farach-Carson et al.
2014; Whitelock et al. 1996).
Given the ability of heparan sulfate-decorated PlnD1
to sequester and deliver rhBMPs and the need to
utilize a more physiologic source of heparan sulfate,
we hypothesized that conjugating PlnD1 to electrospun
PCL scaffolds would increase both the growth factor
loading capacity and the osteoinductivity of the scaf-
fold. To test this, we developed a method to conjugate
PlnD1 onto electrospun PCL fibers and tested the
resulting modified PCL scaffold for increased binding
and delivery of BMP-2 as well as bioactivity in indu-
cing in vitro osteogenesis.
Methods
PlnD1 synthesis and purification
PInD1 was purified and characterized as described previ-
ously (Casper et al. 2007; Yang et al. 2006). PInD1 con-
struct (amino acids 22–194) was designed for the mini-
proteoglycan to be secreted into mammalian cell culture
media for purification. Briefly, stably-transfected HEK 293
EBNA cells (Life Technologies, Carlsbad, CA) were cul-
tured in high glucose Dulbecco’s Modified Eagle Medium
(DMEM) (Life Technologies, Carlsbad, CA) supplemented
with 10 % (v/v) heat-inactivated fetal bovine serum (FBS),
2 mM L-glutamine, 0.2 Units/mL penicillin, 0.2 μg/μL
streptomycin (Life Technologies, Carlsbad, CA), 10 ng/
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Technologies, Carlsbad, CA) and maintained at 37 °C in a
5 % CO2 incubator. Conditioned medium was prepared by
culturing the cells in a HYPERflask® (Corning, Corning,
NY) with DMEM supplemented with 2 % FBS. Condi-
tioned medium that was collected was concentrated using
a 10 kDa molecular weight cutoff spiral wound media
concentrator. The concentrated conditioned medium was
passed twice through a diethylaminoethyl (DEAE) column
at 4 °C, washed extensively in a HEPES buffered solution
(pH 8.0) containing 250 mM NaCl, 0.5 mM phenyl-
methylsulfonyl fluoride (PMSF), 0.5 mM benzamadine,
and 0.2 % (w/v) sodium azide. PlnD1 was eluted from the
column in a similar buffer containing 750 mM NaCl. The
presence of PlnD1 was confirmed by assessing the frac-
tions using a PlnD1-specific A76 and N-20 (Santa Cruz
Biotechnology) antibody dot blot. Subsequently, PlnD1
was concentrated and exchanged into 25 mM HEPES,
pH 7.4, 50 mM NaCl, and 1 % (v/v) glycerol solution
using a 10 kDa molecular weight cutoff centrifugal filter
(Millipore, Billerica, MA), 0.22 μm filtered, aliquoted,
and stored at -80 °C. Purity was assessed through redu-
cing SDS-PAGE (4–12 % acrylamide gradient gels (Life
Technologies, Carlsbad, CA) in 3-(N-morpholino) pro-
panesulfonic acid (MOPS) buffer), Coomassie staining and
N-20 antibody western blots (Additional file 1: Figure S1).
Approximately 20–30 mg at 2 mg/mL of pure PlnD1 was
obtained from 4 L of conditioned medium.
Fabrication of electrospun PCL scaffolds
As previously described, electrospun non-woven poly(ε-
caprolactone) (Lactel, Birmingham, AL) mats (approxi-
mately 1 mm thickness) were fabricated with an average
fiber diameter of approximately 10 μm (Pham et al. 2006a).
Briefly, a syringe pump, power supply, and a grounded,
square copper plate comprise the electrospinning setup.
PCL (inherent viscosity range, 1.0–1.3) was dissolved in a
5:1 (v/v) chloroform/methanol solution to 18 % (w/w), and
filled a 30-mL syringe fitted with a 16-gauge blunt needle.
The needle and copper ring were connected via a split
positive lead from the power supply. The electric field was
stabilized by placing the copper ring between the needle
and copper plate. A glass plate was placed in front of the
copper plate to collect fibers during the electrospinning
process. (Fong et al. 2013) Scanning electron microscopy
(FEI Quanta 400 Environmental) was used to inspect the
gold sputter-coated mats for consistent fiber morphology
and diameter. Individual 3-mm scaffolds were then
punched out of the mats using a dermal biopsy punch.
Functionalization of PCL scaffolds with PlnD1
To conjugate PInD1 onto the surface of electrospun
PCL fibers, the fabricated PCL scaffolds first were pre-
wetted using an ethanol gradient starting with 100 %ethanol. 125I-labeled PInD1 was labeled by Perkin Elmer
Life Sciences (Boston, MA) with >95 % purity and < 5 %
free radiolabeled Iodine. Prewetted PCL fibers then were
hydrolyzed with 0.5 M NaOH for 1 h and then proton-
ated with 0.01 M HCl for 1 min to produce fiber sur-
faces bearing carboxylic groups. Scaffolds then were
incubated in 0.1 M 2-(N-morpholino)ethanesulfonic acid
(MES) (Sigma-Aldrich, St. Louis, MO) buffer for 1 h.
Following this, the scaffolds were incubated in a buffer
solution containing 7.8 mM sulfo-N-hydroxysulfosucci-
nimide (Sulfo-NHS) (Thermo Scientific, Rockville, IL),
39 mM 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
hydrochloride (EDC) (Thermo Scientific, Rockville, IL),
0.5 M NaCl, and 0.1 M MES at pH 6.0 in the presence
of 125I-labeled PInD1 for 3 h. Controls were placed into a
similar buffer solution in the absence of Sulfo-NHS and
EDC. Constructs were then washed 6 times with phos-
phate buffered saline (PBS), and the radioactivity of at-
tached (covalent and non-specific) PlnD1 was measured
using a gamma counter (Cobra II Autogamma, Packard,
Meridian, CT). Constructs were next washed with 1 % (v/
v) Tween-20 in PBS for 24 h with gentle shaking (70 rpm)
to remove any non-covalently bound PlnD1, and radio-
activity (DMPs) was measured again. Qualitative assess-
ment of PlnD1 conjugation was performed by staining the
constructs with Safranin O (1 mg/mL) overnight. Con-
structs were imaged using a digital camera (Nikon D2H)
following a PBS rinse.
rhBMP-2 binding and quantification of in vitro release
kinetics
The release kinetics of rhBMP-2 from PInD1-conjugated
PCL constructs was assessed by measuring the radio-
activity of 125I-labeled rhBMP-2. Briefly, 125I-labeled
rhBMP-2 (Perkin Elmer Life Sciences, Boston, MA) was
incorporated with non-labeled rhBMP-2 (Peprotech,
Rocky Hill, NJ) in 200 μL 3 % BSA in PBS (w/v) at a
hot:cold ratio of 3:97. Constructs first were blocked with
3 % BSA in PBS (w/v) for 3 h at room temperature with
gentle shaking (70 rpm) to minimize non-specific bind-
ing. Following which, each construct was incubated with
the 125I-labeled and non-labeled rhBMP-2 solution (total
of 4 μg rhBMP-2) overnight with gentle shaking (70
rpm) at 37 °C. After the incubation, constructs were
washed thrice with 100 μL 3 % BSA in PBS (w/v) to re-
move any unattached rhBMP-2. The constructs each
then were placed in a 5 ml culture tube (VWR, Radnor,
PA), and a gamma counter was used to measure the ini-
tial amount of rhBMP-2 loaded within each construct.
For 23 days, constructs were incubated with 1 mL of
PBS with gentle shaking (70 rpm) at 37 °C. At days 1, 2,
5, 8, 11, 14, 17, 20, and 23 the supernatant of each con-
struct was collected and replaced with fresh PBS. The
amount of released growth factor was determined by the
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standard curve using the gamma counter.Quantification of released rhBMP-2 bioactivity
To determine the in vitro biological activity of released
rhBMP-2 from the PlnD1-conjugated PCL constructs, a
previously reported method was employed with modifi-
cations (Kempen et al. 2008). This method is based on
the W20–17 mouse bone marrow stromal cell line,
which responds to rhBMP-2 in a dose-responsive man-
ner by increasing alkaline phosphatase activity (Thies
et al. 1992). Over a period of 23 days, medium that was
incubated with the rhBMP-2-releasing PlnD1-conjugated
PCL constructs (or unmodified PCL scaffolds) for 1 day
(for the first two time-points) or 3 days (for the rest of
the time-points) was transferred to fresh W20–17 cell
cultures at designated time-points to determine the
levels of alkaline phosphatase activity.
Cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM) containing 10 % (v/v) fetal bovine
serum and 1 % (from stock) antibiotics/antimycotics. Prior
to the start of the in vitro experiment, W20–17 cells were
expanded and cryopreserved in multiple aliquots. To es-
tablish new cultures for each time-point, an aliquot (pas-
sage 3) was thawed, expanded for 3 days, and re-plated in
24-well plates at a density of 20,000 cells/cm2. Medium
was replaced the next day with medium that had been ex-
posed to the rhBMP-2-releasing PlnD1-conjugated PCL
constructs (or unmodified PCL scaffolds) from the previ-
ous time-point, and cells were incubated with this medium
for 3 days. W20–17 cells were treated with medium con-
taining 0, 10, 50, 100 or 500 ng/mL of rhBMP-2 to verify
the dose-responsive effect of rhBMP-2 on alkaline phos-
phatase activity (positive controls). The collected samples
underwent three cycles of freezing and thawing, and then
were ultrasonicated to lyse the cells. The cell lysates were
subsequently assayed for cellularity and alkaline phosphat-
ase activity. Cellularity was determined by using the
Quant-iT™ PicoGreen® dsDNA assay kit (Invitrogen™) as
per the manufacturer’s instructions. Briefly, cell lysate,
assay buffer, and dye solution were mixed and allowed to
incubate for 10 min at room temperature. Excitation and
emission wavelengths of 485 and 528 nm, respectively,
were used to measure the fluorescence (FLx800 fluores-
cence microplate reader; BioTek Instruments). A lambda
DNA standard curve was used to determine DNA concen-
trations. Alkaline phosphatase activity was measured using
alkaline buffer solution and phosphatase substrate tablets
(Sigma). Briefly, cell lysate and the reagents were mixed
and incubated at 37 °C for 1 h. NaOH was used to stop
the reaction, and absorbance at 405 nm was measured
(PowerWave x340 Microplate Reader; BioTek Instru-
ments). A p-nitrophenol standard curve was used todetermine alkaline phosphatase activity, which then was
normalized to DNA content for each sample.Statistical analysis
Data are presented as mean ± standard deviation for n = 3
throughout the study. One-way analysis of variance
(ANOVA) followed by Tukey’s multiple-comparison test
was used in the analysis of data. p < 0.05 was considered
to indicate a significant difference.Results
Covalent modification of PCL fiber surfaces and
quantification of bound PlnD1
Following a previously established method, reactive groups
were generated on electrospun PCL fiber surfaces via
base-catalyzed hydrolysis of the ester bond in the PCL
backbone followed by conversion of the resulting carboxyl-
ates to carboxylic acid groups with hydrochloric acid
(Hartman et al. 2010). Using sulfo-NHS/EDC-mediated
chemistry, PlnD1 then was coupled to the carboxylated
PCL via free amines within the peptide. Given the presence
of glycosaminoglycan chains on PlnD1, conjugation of the
peptide onto PCL was confirmed by staining the con-
structs with Safranin O in deionized water (Kiviranta et al.
1985). As shown in Fig. 1a, the darker stained construct
corresponded to scaffolds that were treated with EDC/
NHS, indicating the presence of more glycosaminoglycans
and hence, covalently conjugated PlnD1. Notably, Tween-
20 was used to remove any non-covalently bound PlnD1
prior to the staining.
To quantify this conjugation, scaffolds were incubated
with varying amounts of 125I-labeled PInD1, and the
radioactivity of the resulting PlnD1-bound constructs
was measured. In the presence of increasing amounts of
125I-labeled PInD1, a corresponding increase in the amount
of 125I-labeled PInD1 was measured for each construct
(Fig. 1b). Notably, no further increase in the amount of
PlnD1 was observed beyond 32 μg of the peptide in the in-
cubation buffer solution. As non-specific binding of PlnD1
to the modified PCL surfaces also could occur, the con-
structs were treated further with Tween-20 to remove any
non-covalently conjugated PlnD1 before radioactivity was
measured again. A similar trend of increasing construct-
associated 125I-labeled PInD1 with increasing amounts of
125I-labeled PInD1 in the incubation buffer solution was
observed, although at lower levels, indicating that covalent
binding accounts for the attachment of PlnD1 to the modi-
fied PCL surfaces. This difference in the amount of 125I-la-
beled PInD1 detected before and after treatment with
Tween-20 was expressed as the percentage of PlnD1
retained via covalent coupling to the PCL surface. Again,
no further increase in the amount of covalently bound
125I-labeled PInD1 was observed beyond 32 μg, where the
Fig. 1 Covalently conjugating PlnD1 to PCL scaffolds. Panel a shows qualitative confirmation of PlnD1 conjugation to PCL via Safranin O staining.
Scaffold on the bottom was processed with Sulfo-NHS/EDC, which facilitated the reaction of free carboxylic groups on PCL with amines on PlnD1.
Scaffold on the top was unmodified. To quantitatively determine the maximum amount of PlnD1 that could be conjugated to the PCL scaffold,
scaffolds were incubated with 6.4, 19.2, 32, or 64 μg of PlnD1 per scaffold. PBS was used in place of NHS/EDC in the conjugation reaction for the
control (CTRL) group. Panel b shows the amount of PlnD1 detected following a PBS wash, followed by another wash with 1 % Tween-20. The latter
was employed to remove any non-specific binding of PlnD1 on the scaffold. c Covalently bound PInDI in PCL was defined as amount of PlnD1 left on
the scaffold after the Tween-20 wash (covalently conjugated PlnD1) divided by the amount of PlnD1 on the scaffold after the PBS wash (includes both
covalently conjugated and non-specific bound PlnD1) x 100 %. (n = 3) Error bars correspond to standard deviation. Scale bar = 3 mm in (a). (*) indicates
a statistical difference between groups (p < 0.05)
Fig. 2 PInDI-PCL scaffolds increased rhBMP-2 loading. rhBMP-2 loading
efficiency and amount of PlnD1-modified and unmodified PCL
scaffolds following an overnight incubation of the scaffolds with 4
μg of rhBMP-2. Error bars correspond to standard deviation (n = 3).
(***) indicates a statistical difference between groups (p < 0.001)
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(Fig. 1c), suggesting that maximum loading of PlnD1 onto
the modified PCL scaffold could be achieved in the pres-
ence of 32 μg of PlnD1 in the incubation buffer solution.
Quantification of rhBMP-2 loading
After confirming that PlnD1 was covalently coupled to the
electrospun PCL fibers, we next sought to determine if
the presence of PlnD1 on the PCL fiber surface resulted in
a higher rhBMP-2 loading capacity as compared to the
unmodified PCL scaffolds. PlnD1-conjugated constructs
and unmodified PCL scaffolds were incubated with the
same amount of 125I-labeled rhBMP-2 (4 μg), and the
radioactivity of the resulting rhBMP-2-loaded constructs
was measured. Loading capacity was defined as the ratio
of the detected rhBMP-2 in the PlnD1-conjugated con-
structs or unmodified PCL scaffolds over the total
rhBMP-2 initially present in the incubation solution. As
shown in Fig. 2, PlnD1-conjugated PCL constructs exhib-
ited a four-fold higher rhBMP-2 loading capacity (20 %) as
compared to the unmodified PCL scaffolds (5 %), under-
scoring the ability of the heparan sulfate chains on the
conjugated PlnD1 to sequester the growth factor and in-
crease rhBMP-2 loading efficiency relative to unmodified
scaffolds. PlnD1-conjugated PCL constructs initially
bound 809 ± 19 ng of rhBMP-2 in contrast with PCL only
scaffolds that bound 233 ± 21 ng of rhBMP-2.
Quantification of rhBMP-2 release kinetics
The absolute amount (Fig. 3) and cumulative release
(Additional file 1: Figure S3) profile of rhBMP-2 (as
measured by radioactive 125I-labeled rhBMP-2) over 23
days of either the PlnD1-conjugated PCL constructs or
unmodified PCL scaffolds shown that PlnD1-conjugatedPCL constructs provided sustained release of rhBMP-2
in PBS. The amount of rhBMP-2 released by the PlnD1-
conjugated PCL constructs was statistically higher than
that of the unmodified PCL scaffolds at all time-points.
Bioactivity of released rhBMP-2
The bioactivity of rhBMP-2 released from the PlnD1-
conjugated PCL constructs was determined by measuring
the ability of the released growth factor to induce ALP ac-
tivity in the W20–17 mouse bone marrow stromal cells.
Fresh cultures were used for each time-point for the
evaluation. Figure 4a depicts the fold change in DNA-
normalized ALP over basal ALP levels in the W20–17
cells. rhBMP-2 released from the PlnD1-conjugated PCL
constructs induced a significantly higher ALP activity over
basal levels as compared to the unmodified PCL scaffolds
Fig. 3 PInDI modified scaffolds controlled rhBMP-2 release. The
absolute amount of rhBMP-2 released from PlnD1-conjugated or
unmodified PCL scaffolds over 23 days. (n = 3) Error bars correspond to
standard deviation. (*) indicates a statistical difference between groups
(p < 0.05)
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proliferation between groups (Additional file 1: Figure S3).
Using a standard curve generated by exposing the
W20–17 cells to known amounts of rhBMP-2 in cul-
ture medium, the amount of bioactive rhBMP-2 re-
leased at each time-point was obtained, as shown in
Fig. 4b. According to this method of detection, PlnD1-
conjugated PCL constructs released significantly more
bioactive rhBMP-2 than unmodified PCL scaffolds up
to day 14. There is a modest difference at day 20 and
day 23.
Discussion
Although rhBMP-2 and rhBMP-7 are available for use in
the clinic for orthopedic regenerative procedures, their
use is generally currently limited by high costs and the
need for supra-physiologic levels, as well as inadequateFig. 4 PInDI-PCL scaffold preserved rhBMP-2 bioactivity. a ALP activity of W
conjugated or unmodified PCL scaffolds. Fresh W20–17 cultures were used
expressed as a fold-change over basal ALP activity. b Amount of bioactive
measured by comparing against a rhBMP-2 dose response curve generated
(n = 5) Error bars correspond to standard deviation. (*) indicates a statisticacontrol over bone healing and a risk of inflammation
(Luginbuehl et al. 2004; DeCarlo and Whitelock 2006;
Lee et al. 2012). To address these problems, efforts have
been directed towards developing rhBMP delivery systems
capable of localizing and modulating the release of the
morphogenetic stimulus for safe and consistent clinical
success. While growth factor delivery strategies based on
physical adsorption, ionic complexation, or covalent
immobilization have been investigated, these approaches
are generally associated with the risk of undesired reduc-
tion in bioactivity and bolus induced attraction of inflam-
matory cells. An alternative strategy is to harness the
innate function of heparan sulfate proteoglycans in the na-
tive ECM to sequester and modulate the availability and
activity of morphogens or growth factors such as rhBMP-2
(DeCarlo and Whitelock 2006). While this approach has
been investigated in the form of heparin incorporation to
scaffolds, such as those based on poly(L-lactic-co-glycolic
acid) (Jeon et al. 2007), chitosan (Engstrand et al. 2008),
fibrin (Yang et al. 2010) and PCL (Kim et al. 2014) to de-
liver rhBMP-2, the use of heparin to deliver growth factors
has limited physiological relevance. Moreover, the effect of
heparin on rhBMP-2 biological activity is mixed–while it
has been reported to enhance the biological activity of
rhBMP-2, it also has been reported to inhibit rhBMP-2
binding to its receptor and reduce rhBMP-2 osteogenic
signaling, underscoring the need to review the suitabil-
ity of using heparin as a rhBMP-2 carrier (Kanzaki
et al. 2008; Jiao et al. 2007; Takada et al. 2003). More-
over, heparin has limited susceptibility to heparanase
digestion (Meikle et al. 2005).
Yet to be fully appreciated, the entity that stores, stabi-
lizes, and presents growth factors in more active config-
urations to their receptors is not heparin, but rather the
heparan sulfate chains associated with proteoglycans on
cell surfaces and the ECM (Decarlo et al. 2012; Casu20–17 cultures exposed to rhBMP-2 released from either PlnD1-
for each time-point. ALP activity was normalized to DNA content and
rhBMP-2 released from PlnD1-modified or unmodified PCL scaffolds as
by adding rhBMP-2 directly to W20–17 cultures (positive control).
l difference between groups (p < 0.05)
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a highly conserved ECM component in bone vasculature
and bone marrow stroma, which is also associated with
bone healing, as the perlecan gene was reported to be
one of the earliest genes expressed in new fracture
callous formation in fractured bone (Wang et al. 2006;
Farach-Carson et al. 2014). Leveraging the prevalence of
perlecan in bone healing, the physiological relevance of
using heparan sulfate-decorated PlnD1 to sequester and
release rhBMP-2 and the previously demonstrated utility
of electrospun PCL scaffolds for bone regeneration, we
have developed a novel rhBMP-2 delivery system for
bone regeneration applications. An injectable form of
this combined with hyaluronan was recently shown by
our group to potentiate the cartilage repair effect of
rhBMP-2 in an experimental model of osteoarthritis
(Srinivasan et al. 2012).
The goal of this study was to determine if functionaliza-
tion of electrospun PCL fibers with PlnD1 enhances
rhBMP-2 binding and if subsequently released rhBMP-2
presents bioactivity. To achieve this, we employed a previ-
ously reported method from our laboratory (Hartman et al.
2010) to conjugate proteins onto PCL surfaces (i.e., via the
introduction of carboxylate groups to surface-hydrolyzed
PCL and the use of EDC/NHS chemistry) and demon-
strated that the presence of covalently attached PlnD1 in-
deed increases the rhBMP-2 loading capacity of
electrospun PCL scaffolds and bioactive release as com-
pared to controls with physically adsorbed rhBMP-2. We
first fabricated PlnD1-conjugated electrospun PCL con-
structs and compared the rhBMP-2 loading efficiency to
that of unmodified PCL. In the presence of conjugated
PlnD1, the rhBMP-2 loading efficiency was approximately
four-fold higher, indicating the ability of PlnD1 to signifi-
cantly enhance the loading capacity of electrospun PCL
scaffolds. This increase likely is reflective of the increase in
the number of rhBMP-2 binding sites due to multivalency
in the presence of the three heparan sulfate chains in PlnD1
(Jha et al. 2009). That covalently conjugated PlnD1 in-
creases the rhBMP-2 binding capacity of PCL scaffolds and
mirrors the findings of a previous study in which rhBMP-2
loading onto hyaluronan hydrogel microparticles was aug-
mented in the presence of PlnD1 (Jha et al. 2009). Fur-
thermore, with the use of heparitinase, it was
demonstrated that rhBMP-2 binding was heparan sulfate-
dependent (Jha et al. 2009). Comparing the increase in
rhBMP-2 binding capacity due to PlnD1 in this study to
one of the two major methods of attaching growth factors
or morphogens onto the surface of scaffolds–chemical
conjugation directly onto the material surface (the other
being physical adsorption)–we found that this increase in
rhBMP-2 binding capacity due to PlnD1 is comparable to
that reported by Zhang et al., where rhBMP-2 was
chemically conjugated directly onto PCL scaffolds(approximately 4-fold higher than physically adsorbed
rhBMP-2).(Zhang et al. 2010) Notably, beyond the indica-
tion that the use of PlnD1 to augment rhBMP-2 loading is
as effective as chemically conjugating the growth factor
directly onto the material surface, the heparan sulfate
chains may provide the additional beneficial effect of po-
tentiating the bioactivity of the delivered rhBMP-2, not
achievable with just delivery of the growth factor alone.
While the presence of PlnD1 resulted in a higher
rhBMP-2 loading capacity as compared to plain un-
modified PCL, the release pattern of the growth fac-
tor was similar between the two groups. The release
kinetics were characterized by a rapid initial release
followed by a slow, sustained release over 23 days. By
covalent coupling of PlnD1 to hyaluronan microparti-
cles, it was previously demonstrated that the presence
of PlnD1 diminished the initial burst release of
rhBMP-2 from non-functionalized microparticles,
resulting in a more linear and sustained rhBMP-2
release.(Jha et al. 2009) In another study where elec-
trospun PCL fibers were modified with heparin-
dopamine for the delivery of rhBMP-2, the authors
reported that the presence of heparin resulted in the
absence of a high initial burst release of the growth
factor. However, the release kinetics of rhBMP-2 from
plain unmodified PCL was not presented for compari-
son against the heparin-modified constructs (Kim
et al. 2014). These studies and others suggest that the
presence of heparan sulfate-decorated PlnD1 or hep-
arin is associated with a dampened initial growth fac-
tor release. However, in our study, while enhanced
rhBMP-2 loading was observed, a reduction in initial
release kinetics was not, in the presence of PlnD1. This
is potentially due to the presence of physically adsorbed
PlnD1, which can also bind rhBMP-2 in addition to the
covalently conjugated PlnD1. Upon incubation, the im-
mediate desorption of physically adsorbed, rhBMP-2-
binding PlnD1 from the PCL surface could have con-
tributed to the initial burst release. Accordingly, be-
cause the ability of PlnD1 to sequester rhBMP-2 may
have been masked by the desorption of physically
adsorbed PlnD1, the release kinetics of rhBMP-2 from
PlnD1-conjugated and plain unmodified PCL scaffolds
are not different. It is noteworthy though that only 59.7
± 1.2 % rhBMP-2 in the loading solution was released
at the end of 23 days in this study. As discussed above,
the amount of rhBMP-2 released from PlnD1-
conjugated microparticles was close to 70 % at the end
of 15 days while in another study where rhBMP-2 was
coated onto polystyrene/PCL fibers, the amount of
rhBMP-2 released after 2 weeks was also approximately
70 %. Although these systems differ, these comparisons
indicate that PlnD1-conjugated PCL constructs are cap-
able of long-term retention of rhBMP-2; the remaining
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be released with extended incubation, or by the activity
of heparanases (Jha et al. 2009).
Using the W20–17 mouse bone marrow stromal cell
line, the bioactivity of released BMP-2 from the
PlnD1-conjugated PCL constructs and unmodified
PCL scaffolds was assessed by determining the ability
of the released growth factor to induce ALP activity
over basal levels in the W20–17 cells and comparing
the detected ALP levels to a standard curve generated
by exposing the cells to known amounts of rhBMP-2.
Even though the amount of rhBMP-2 released from
the PlnD1-conjugated constructs was significantly
greater than the unmodified PCL scaffolds at all time-
points (up to day 23), ALP activity induced in the
W20–17 cultures was only significantly higher up to
day 14. The biphasic profile often is observed in
many growth factor release systems in which simple
diffusion governs the growth factor release (Jha et al.
2009). This is likely because this assay may have lim-
ited sensitivity at the later time-points where the dif-
ferences in BMP-2 released between the groups are
small. Additionally, the release kinetics in serum
might be slightly different than PBS since high pro-
tein environment might interfere with the protein
bindings. Given the ability of the BMP-2 released to
induce an increase in ALP activity over basal levels in
the W20–17 cells in both systems, this indicates that
the released protein is stable and that structural integ-
rity is maintained (Kempen et al. 2008). By conjugating
heparin-dopamine onto PCL fibers to deliver rhBMP-
2, Kim et al. reported that the rhBMP-2 binding
heparin-conjugated PCL fibers could significantly in-
duce greater osteogenic differentiation in periodontal
ligament cells relative to PCL fibers alone, corroborat-
ing the findings of our study. Notably, the PCL-only
control in this aforementioned study was not physic-
ally adsorbed with rhBMP-2, and cells were seeded
directly onto the scaffolds (Kim et al. 2014). Taken
together, these results indicate that rhBMP-2 released
from PlnD1-functionalized PCL fibers maintains
structural integrity and bioactivity necessary to confer
osteoinductive properties to PCL fiber scaffolds.
Conclusions
In this study, we report a novel method to efficiently co-
valently conjugate heparan sulfate-decorated PlnD1 to
the surface of electrospun PCL fibers for rhBMP-2 bind-
ing and controlled release. Covalently conjugated hepa-
ran sulfate-decorated PlnD1 significantly increased the
loading capacity and retention of rhBMP-2 in electro-
spun PCL scaffolds and subsequently maintained the
in vitro osteogenic activity of the released growth factor.
The increased loading capacity of the PCL scaffold inthe presence of PlnD1 underscores the potential for use
of rhBMP-2 in tissue engineering applications. More im-
portantly, we demonstrate that in place of heparin,
physiologically relevant heparan sulfate-decorated PlnD1
is a useful adjunct to PCL scaffolds for rhBMP-2 delivery
and potential enhancement of bioactivity for bone tissue
regeneration without adverse effects of high local con-
centrations of rhBMP-2.Additional file
Additional file 1: Figure S1. Perlecan domain I (Dm1) purification and
glycosaminoglycan characterization. Perlecan Dm1 purified from HEK293
cells was incubated alone (lanes 2, 9) or with heparitinases 1, 2, 3 and
chondroitinase ABC either together (lanes 3, 10) or separately (lanes 5–8).
Lane 1 is the molecular weight marker and Lane 4 is all enzymes without
Dm1. On the left is a Coomassie stain (lanes 1–8) and on the right is a
western blot (lanes 9–10) using a domain I specific antibody (N-20).
The arrow head indicates the glycosylated form of Dm I and the arrow
indicates the protein core. All enzymes were incubated at 0.1 Units per
10 μg of Dm 1 in a 20 μL of reaction at 37 °C for 4 h. The buffer was 20 mM
Tris-HCl, 10 mM NaCl, and 3 mM calcium acetate at pH 8.0. Figure S2. PInDI
modified scaffolds controlled rhBMP-2 cumulative release. The absolute
amount of rhBMP-2 released from PlnD1-conjugated or unmodified PCL
scaffolds over 23 days. (n = 3) Error bars correspond to standard deviation.
Figure S3. DNA concentration of W20–17 cells after exposing to rhBMP-2
released from either PlnD1-conjugated or unmodified PCL scaffolds. Fresh
W20–17 cultures were used for each time-point (n = 5). (DOCX 227 kb)
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